QUALITY ASSESSMENT OF INDOMETHACIN CAPSULES MARKETED BY BANGLADESHI PHARMACEUTICAL INDUSTRIES

G.M.M.  Murshid; D.R.  Paul; M.G  Hossain; A.A  Rahman; M.  Saifuzzaman; M.M.  Sarder

doi:10.53808/KUS.2006.7.1.0511-L

Authors

G.M.M. Murshid Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
D.R. Paul Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
M.G Hossain Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
A.A Rahman Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
M. Saifuzzaman Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh
M.M. Sarder Pharmacy Discipline, Life Science School, Khulna University, Khulna 9208, Bangladesh

DOI:

https://doi.org/10.53808/KUS.2006.7.1.0511-L

Keywords:

Capsule, Indomethacin, dissolution test, potency, pharmaceuticals, Bangladesh

Abstract

In Bangladesh about nineteen different Indomethacin marketed preparations (including capsule and suppository) are available. Of them nine brands are Indomethacin capsule dosage forms, potency of which was assayed by UV spectrophotometry and dissolution study was carried out according to the USP pharmacopoeial method to evaluate their quality. The result showed that eight brands of capsules (89%) met the USP specification of potency and the remaining one brand was less potent. All brands were tested for dissolution rate and two brands (23%) failed to meet the specification for dissolution rate. Additional in-vivo bioavailability studies are of utmost importance to draw more conclusive finding regarding quality status of the Indomethacin preparations.

Downloads

Download data is not yet available.

References

Anon. 2000a. The Official Compendia of Standards USP 24, NF 19 (2000). The United States Pharmacopeial Convention, USP (United States Pharmacopeia) 24. Asian edition, Tata Donnelley Limited, India, pp. 941-943.

Anon. 2000b. British Pharmacopoeia Commission, British Pharmacopoeia (BP). London Her Majesty’s Stationery Office (General notices section, CD-ROM Ver. 4.0, May 2000), London, A: 214- 219.

Clench, J.; Reinberg, A., Ghata, J. and Smolensky M. 1981. Circadian changes in the bioavailability and effects of Indomethacin in healthy subjects. European Journal of Clinical Pharmacology, 20: 359-369.

Guisson, P.; Cuisinaud, G.; Llorca, Lejeune, E. and Sessard, J. 1983.Chronopharmacokinetic study of a prolonged release form of Indomethacin. European Journal of Clinical Pharmacology, 24: 667-670.

Hardman, G.; Limbird, L. E. and Gilman A.G. 1996. Goodman and Gilman’s The Pharmacological Basis of Therapeutics. 10th edn., The McGraw-Hill Companies, New York, pp. 633-634.

Miyagawa, Y.; Okabe, T.; Yamaguchi, Y.; Miyajima, M.; Sato, H. and Sudana, H. 1996. Controlled release of Diclofenac sodium from wax matrix granule. International Journal of Pharmaceutics, 138: 215-224.